CNS Specific Antisense Oligonucleotide Market - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

CNS Specific Antisense Oligonucleotide Market - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Antisense oligonucleotides are synthetic strings of nucleic acid, which reduce expression of messenger RNA (m-RNA). The function performed by interference with pre m- RNA splicing are restoration of protein and modification of protein. Antisense oligonucleotide is a new approach to treat several neurodegenerative disorders to prevent disease onset or stop disease development.

Market Dynamics

Increasing prevalence of neurodegenerative disease is a major factor driving CNS specific antisense oligonucleotide market growth. According to fact sheet from Alzheimer Association, an estimated around 5.7 million Americans were diagnosed with Alzheimer's dementia in 2018. Moreover, rich product pipeline for the treatment of CNS disorders and rare diseases associated with it is expected to boost the market growth. For instance, in December 2018, Biogen and Ionis Pharmaceuticals product IONIS-SOD1Rx (BIIB067) cleared Phase 1 clinical trial and is expected to be launched by 2020.

Key features of the study:

  • This report provides in-depth analysis of the CNS specific antisense oligonucleotide market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global CNS specific antisense oligonucleotide market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Stroke Therapeutic Inc., Dynacure, ProQR Therapeutics N.V., Q-STATE BIOSCIENCES, INC.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global CNS specific antisense oligonucleotide market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the CNS specific antisense oligonucleotide market
Detailed Segmentation:
  • Global CNS Specific Antisense Oligonucleotide Market, By Drug:
  • Approved
  • Patisiran
  • Nusinersen
  • Inotersen
  • Pipeline
  • IONIS-HTT Rx (RG6042)
  • Global CNS Specific Antisense Oligonucleotide Market, By Indication:
  • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
  • Spinal Muscular Atrophy
  • Huntington’s Disease
  • Global CNS Specific Antisense Oligonucleotide Market, By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Global CNS Specific Antisense Oligonucleotide Market, By Geography:
  • North America
  • By Drug:
  • Approved
  • Patisiran
  • Nusinersen
  • Inotersen
  • Pipeline
  • IONIS-HTT Rx (RG6042)
  • By Indication:
  • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
  • Spinal Muscular Atrophy
  • Huntington’s Disease
  • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • By Country:
  • U.S.
  • Canada
  • Latin America
  • By Drug:
  • Approved
  • Patisiran
  • Nusinersen
  • Inotersen
  • Pipeline
  • IONIS-HTT Rx (RG6042)
  • By Indication:
  • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
  • Spinal Muscular Atrophy
  • Huntington’s Disease
  • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Drug:
  • Approved
  • Patisiran
  • Nusinersen
  • Inotersen
  • Pipeline
  • IONIS-HTT Rx (RG6042)
  • By Indication:
  • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
  • Spinal Muscular Atrophy
  • Huntington’s Disease
  • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Drug:
  • Approved
  • Patisiran
  • Nusinersen
  • Inotersen
  • Pipeline
  • IONIS-HTT Rx (RG6042)
  • By Indication:
  • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
  • Spinal Muscular Atrophy
  • Huntington’s Disease
  • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • By Country:
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • By Drug:
  • Approved
  • Patisiran
  • Nusinersen
  • Inotersen
  • Pipeline
  • IONIS-HTT Rx (RG6042)
  • By Indication:
  • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
  • Spinal Muscular Atrophy
  • Huntington’s Disease
  • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Drug:
  • Approved
  • Patisiran
  • Nusinersen
  • Inotersen
  • Pipeline
  • IONIS-HTT Rx (RG6042)
  • By Indication:
  • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
  • Spinal Muscular Atrophy
  • Huntington’s Disease
  • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • By Country:
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • Alnylam Pharmaceuticals Inc.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Highlights
  • Market Strategies
  • Sarepta Therapeutics Inc.
  • Biogen Inc.
  • Ionis Pharmaceuticals Inc.
  • Wave Life Sciences Ltd.
  • Stroke Therapeutic Inc.
  • Dynacure
  • ProQR Therapeutics N.V.
  • Q-STATE BIOSCIENCES, INC.
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug
Market Snippet, By Indication
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Pipeline Analysis
Reimbursement Scenario
Epidemiology
Pest Analysis
4. Global CNS Specific Antisense Oligonucleotide Market, By Drug, 2018 – 2026, (US$ Mn)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Approved
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Patisiran
Nusinersen
Inotersen
Pipeline
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
IONIS-HTT Rx (RG6042)
5. Global CNS Specific Antisense Oligonucleotide Market, By Indication, 2018 – 2026, (US$ Mn)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Spinal Muscular Atrophy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Huntington’s Disease
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
6. Global CNS Specific Antisense Oligonucleotide Market, By Distribution Channel, 2018 – 2026, (US$ Mn)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Hospital Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Retail Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Online Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
7. Global CNS Specific Antisense Oligonucleotide Market, By Region, 2018 – 2026, (US$ Mn)
Introduction
Market Share Analysis, By Region, 2018 and 2026 (%)
Y-o-Y Growth Analysis, For Regions, 2017–2026
North America
Market Size and Forecast, By Drug, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Indication, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
U.S.
Canada
Latin America
Market Size and Forecast, By Drug, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Indication, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Market Size and Forecast, By Drug, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Indication, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Drug, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Indication, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of APAC
Middle East
Market Size and Forecast, By Drug, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Indication, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
Market Size and Forecast, By Drug, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Indication, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
South Africa
Central Africa
North Africa
8. Competitive Landscape
Heat Map Analysis
Company Profiles
Alnylam Pharmaceuticals Inc.
Company Overview
Drug Portfolio
Financial Overview
Key Highlights
Market Strategies
Sarepta Therapeutics Inc.
Company Overview
Drug Portfolio
Financial Overview
Key Highlights
Market Strategies
Biogen Inc.
Company Overview
Drug Portfolio
Financial Overview
Key Highlights
Market Strategies
Ionis Pharmaceuticals Inc.
Company Overview
Drug Portfolio
Financial Overview
Key Highlights
Market Strategies
Wave Life Sciences Ltd.
Company Overview
Drug Portfolio
Financial Overview
Key Highlights
Market Strategies
Stroke Therapeutic Inc.
Company Overview
Drug Portfolio
Financial Overview
Key Highlights
Market Strategies
Dynacure
Company Overview
Drug Portfolio
Financial Overview
Key Highlights
Market Strategies
ProQR Therapeutics N.V.
Company Overview
Drug Portfolio
Financial Overview
Key Highlights
Market Strategies
Q-STATE BIOSCIENCES, INC.
Company Overview
Drug Portfolio
Financial Overview
Key Highlights
Market Strategies
Analyst Views
9. Section
References
Research Methodology
About us and Sales Contact
*Browse 38 market data tables and 32 figures on "CNS Specific Antisense Oligonucleotide Market - Global forecast to 2026”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook